Georg Schett, MD, presented the latest research into CAR T cell therapy for rheumatic diseases, such as systemic lupus erythematosus & other conditions. These findings demonstrate remarkable and durable efficacy for the treatment, as well as the potential for disease remission in some patients.
SAN DIEGO—As part of a panel on systemic autoinflammatory diseases (SAIDs) at a Nov. 15 scientific session of ACR Convergence 2023, Sivia Lapidus, MD, shared context and insights on the therapeutic management of patients with these conditions. The Spectrum of SAIDs SAIDs encompass a broad swath of individually rare disorders driven by innate immune responses…
SAN DIEGO—In one presentation at Plenary Session 3, ACR Convergence 2023, Beth Wallace, MD, MSc, a staff physician at the VA Ann Arbor Healthcare System, Michigan, and an assistant professor at the University of Michigan, Ann Arbor, shared important data on the relationship between time-dependent cumulative glucocorticoid exposure and major adverse cardiovascular events (MACE) in a cohort of veterans with rheumatoid arthritis (RA).
Expressing empathy, engaging patients in conversations about their emotional health and having an overall understanding of grief can help rheumatology health professionals better care for their patients. During a session at ACR Convergence 2023, mental health professionals and patients highlighted how grief affects patients with rheumatic disease and how providers can respond.
SAN DIEGO—During ACR Convergence 2023 in November, the ACR and the ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist profiles the recipients of the ARP Merit Awards and ARP Master class, recognizing outstanding contributions to the field of rheumatology. The…
A panel of experts, including ACR on Air Host Jonathan Hausmann, MD, provided tips and insights into creating a podcast and engaging with an audience.
Researchers and physician-scientists often need practical advice for getting their work published. Here are insights into how to select an appropriate publication, manage co-author relationships and more from a panel of experts in both rheumatology and publishing.
An array of new and expanded indications of therapeutics for rheumatic disease last year relied on pharmacokinetic modeling for intravenous dosing and efficacy extrapolation for pediatric populations.
A study found the continuation of tumor necrosis factor inhibitor (TNFi) treatment in patients with chronic rheumatic inflammatory diseases after pregnancy diagnosis was not associated with worse outcomes than those who discontinued treatment with TNFi’s.
Speakers discussed common payer practices and policies that rheumatologists must navigate to secure and maintain appropriate care for their patients, including pharmacy benefit managers and prior authorization.